1. Home
  2. Documents
  3. Interim statement on hybrid immunity and increasing population seroprevalence rates (SARS-CoV-2)

Interim statement on hybrid immunity and increasing population seroprevalence rates (SARS-CoV-2)

Interim statement on hybrid immunity and increasing population seroprevalence rates (SARS-CoV-2)
Dowload from WHO Digital Library

The World Health Organization (WHO) with the support of the Strategic Advisory Group of Experts (SAGE) on Immunization and its COVID-19 Vaccines Working Group, continues to review the emerging evidence on the increasing seroprevalence rates against SARS-CoV-2 globally and the characteristics and potential benefits of hybrid immunity.

This statement reflects the current understanding of hybrid immunity and highlights the gaps in evidence and potential implications for vaccination schedules and strategies.